In this episode of CFO Weekly, Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, joins Megan Weis to explore how finance leaders can modernize their organizations through technology while keeping people, flexibility, and fit-for-purpose thinking at the center of every decision drawing from more than two decades of building finance infrastructure in the San Diego biotech sector.
In this episode of CFO Weekly, Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, joins Megan Weis to explore how finance leaders can modernize their teams through technology while keeping people at the center of transformation. Lineage Cell Therapeutics is a biotech company developing innovative cell therapies for conditions including spinal cord injury, age-related macular degeneration, and cancer.
Jill brings more than two decades of leadership experience across biotechnology and pharmaceutical organizations, with deep expertise in building operational infrastructure, scaling finance functions, and partnering with executive teams to execute long-term strategic vision. Having helped grow Gossamer Bio from six employees to over 200 and currently serving as CFO at Lineage Cell Therapeutics for nearly four years, Jill shares how she evaluates technology investments, fosters team adoption, and ensures that automation serves people rather than replacing them.
What You’ll Learn:
- Why investing in people remains the foundation of finance innovation
- How to evaluate and choose technology that fits your organization’s size and maturity
- Where the biggest automation opportunities exist in biotech and healthcare finance
- How to introduce new technologies without overwhelming a lean team
- What skills modern finance professionals need to stay relevant
- Why AI will not replace finance teams and what it will change instead
- How to build a collaborative CFO relationship with the rest of the business
Learn More About Jill: